Skip to main content

Table 3 Association between cumulative periods of exposure to and time since discontinuation of TA and ddI with adipose tissue density

From: Long-lasting alterations in adipose tissue density and adiponectin production in people living with HIV after thymidine analogues exposure

  VAT density p-value SAT density p-value
Adjusted β* [95% CI]   Adjusted β** [95% CI]  
Cumulative time of exposure to TA and/or ddI
 <3.6 years Ref   Ref  
 3.6–6.3 years 1.0 [−0.5;2.5] 0.198 −1.0 [−2.4;0.3] 0.141
 6.4–9.2 years 0.2 [− 1.3;1.8] 0.770 −2.8 [−4.2;-1.4] < 0.001
 >9.2 years − 0.5 [− 2.1;1.2] 0.578 −2.3 [−3.8;-0.9] 0.001
Time since discontinuation of TA and/or ddI
 <8.1 years Ref   Ref  
 8.1–9.6 years −0.3 [− 1.8;1.2] 0.702 −0.0 [− 1.4;1.4] 0.965
 9.7–10.7 years 1.4 [− 0.1;2.9] 0.074 0.4 [− 1.1;1.8] 0.593
 >10.7 0.6 [− 1.0;2.1] 0.460 −0.6 [− 2.0;0.9] 0.431
  1. β coefficients represent the degree of change in HU of VAT and SAT, respectively, associated with each level of the explanatory variables
  2. Abbreviations: visceral adipose tissue, VAT; subcutaneous adipose tissue, SAT; thymidine nucleoside analog reverse-transcriptase inhibitors, TA; confidence interval, CI
  3. All the models were adjusted for age, sex, origin, physical activity, smoking, BMI, cumulative time of exposure to TA and/or ddI, time since discontinuation of TA and/or ddI, VAT area* (or SAT area**)